205 related articles for article (PubMed ID: 10321453)
1. Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats.
Friedman JE; Ishizuka T; Liu S; Farrell CJ; Koletsky RJ; Bedol D; Ernsberger P
Blood Press Suppl; 1998; 3():32-9. PubMed ID: 10321453
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB).
Ernsberger P; Ishizuka T; Liu S; Farrell CJ; Bedol D; Koletsky RJ; Friedman JE
J Pharmacol Exp Ther; 1999 Jan; 288(1):139-47. PubMed ID: 9862764
[TBL] [Abstract][Full Text] [Related]
3. The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X.
Velliquette RA; Ernsberger P
J Pharmacol Exp Ther; 2003 Aug; 306(2):646-57. PubMed ID: 12756274
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathology in the obese spontaneous hypertensive Koletsky rat: a model of syndrome X.
Ernsberger P; Koletsky RJ; Friedman JE
Ann N Y Acad Sci; 1999 Nov; 892():272-88. PubMed ID: 10842668
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X.
Velliquette RA; Friedman JE; Shao J; Zhang BB; Ernsberger P
J Pharmacol Exp Ther; 2005 Jul; 314(1):422-30. PubMed ID: 15833894
[TBL] [Abstract][Full Text] [Related]
6. Contrasting metabolic effects of antihypertensive agents.
Velliquette RA; Ernsberger P
J Pharmacol Exp Ther; 2003 Dec; 307(3):1104-11. PubMed ID: 14557373
[TBL] [Abstract][Full Text] [Related]
7. Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent.
Ernsberger P; Koletsky RJ; Collins LA; Bedol D
Cardiovasc Drugs Ther; 1996 Jun; 10 Suppl 1():275-82. PubMed ID: 8827950
[TBL] [Abstract][Full Text] [Related]
8. The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.
Ernsberger P; Friedman JE; Koletsky RJ
J Hypertens Suppl; 1997 Jan; 15(1):S9-23. PubMed ID: 9050981
[TBL] [Abstract][Full Text] [Related]
9. Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine.
Sun Z; Ernsberger P
J Pharmacol Exp Ther; 2007 Feb; 320(2):845-52. PubMed ID: 17095615
[TBL] [Abstract][Full Text] [Related]
10. Reduced insulin receptor signaling in the obese spontaneously hypertensive Koletsky rat.
Friedman JE; Ishizuka T; Liu S; Farrell CJ; Bedol D; Koletsky RJ; Kaung HL; Ernsberger P
Am J Physiol; 1997 Nov; 273(5):E1014-23. PubMed ID: 9374689
[TBL] [Abstract][Full Text] [Related]
11. Cardiac effects of moxonidine in spontaneously hypertensive obese rats.
Mukaddam-Daher S; Menaouar A; El-Ayoubi R; Gutkowska J; Jankowski M; Velliquette RA; Ernsberger P
Ann N Y Acad Sci; 2003 Dec; 1009():244-50. PubMed ID: 15028594
[TBL] [Abstract][Full Text] [Related]
12. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
Chazova I; Almazov VA; Shlyakhto E
Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753
[TBL] [Abstract][Full Text] [Related]
13. Selective imidazoline agonist moxonidine in obese hypertensive patients.
Sanjuliani AF; de Abreu VG; Francischetti EA
Int J Clin Pract; 2006 May; 60(5):621-9. PubMed ID: 16700870
[TBL] [Abstract][Full Text] [Related]
14. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats.
Zhao M; Li Y; Wang J; Ebihara K; Rong X; Hosoda K; Tomita T; Nakao K
Diabetes Obes Metab; 2011 Dec; 13(12):1123-9. PubMed ID: 21749604
[TBL] [Abstract][Full Text] [Related]
15. Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study.
Mikulášková B; Holubová M; Pražienková V; Zemenová J; Hrubá L; Haluzík M; Železná B; Kuneš J; Maletínská L
Nutr Diabetes; 2018 Jan; 8(1):5. PubMed ID: 29339795
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
Prichard BN; Owens CW; Graham BR
J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats.
Henriksen EJ; Jacob S; Fogt DL; Youngblood EB; Gödicke J
Hypertension; 1997 Dec; 30(6):1560-5. PubMed ID: 9403583
[TBL] [Abstract][Full Text] [Related]
18. Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.
Velliquette RA; Kossover R; Previs SF; Ernsberger P
Naunyn Schmiedebergs Arch Pharmacol; 2006 Jan; 372(4):300-12. PubMed ID: 16416266
[TBL] [Abstract][Full Text] [Related]
19. Effects of aglycone genistein in a rat experimental model of postmenopausal metabolic syndrome.
Bitto A; Altavilla D; Bonaiuto A; Polito F; Minutoli L; Di Stefano V; Giuliani D; Guarini S; Arcoraci V; Squadrito F
J Endocrinol; 2009 Mar; 200(3):367-76. PubMed ID: 19066292
[TBL] [Abstract][Full Text] [Related]
20. The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X.
Koletsky RJ; Velliquette RA; Ernsberger P
Ann N Y Acad Sci; 2003 Dec; 1009():251-61. PubMed ID: 15028595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
